PRTK Paratek Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 01 April 2020 Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for Security Requirements and U.S. Onshoring of the Manufacturing Supply Chain for NUZYRA• (omadacycline)

   BOSTON, April 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for

2. 10 March 2020 Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA• (omadacycline)

   BOSTON, March 10, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for

3. 02 March 2020 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

   BOSTON, March 02, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for

4. 26 February 2020 Paratek Pharmaceuticals to Present at the SVB Leerink 9th Annual Global Healthcare Conference

   BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for

5. 25 February 2020 Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million

   -- Paratek Expects Full Year 2020 Total Revenues to be Between $75 and $80 Million including NUZYRA Net Sales of Approximately $66 Million   -- Paratek Now Anticipates its Cash Runway Will Extend Through the End of 2023

6. 24 February 2020 Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China Region

   BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for

7. 18 December 2019 Paratek Awarded BARDA Project BioShield Contract for NUZYRA®

   - Total award valued at up to $285 million  - Paratek to host a conference call today, December 18, 2019 at 5:30 p.m. EST BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a

8. 02 December 2019 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

   BOSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

9. 12 November 2019 Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019

   -- Third Quarter 2019 NUZYRA® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million -- -- Oral-only CABP Pharmacokinetics Study Initiated-- BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Paratek

10. 01 November 2019 Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

11. 31 October 2019 Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections

    BOSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced

12. 01 October 2019 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

13. 01 October 2019 Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

    WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven

14. 09 September 2019 Paratek Mourns Passing of Co-founder Dr. Stuart Levy

    BOSTON, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) mourns the loss of Stuart Levy, M.D., who passed way last week. Dr. Levy co-founded the company more than two decades ago along

15. 04 September 2019 Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    BOSTON, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

16. 03 September 2019 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

17. 26 August 2019 Paratek Pharmaceuticals to Present at Robert W. Baird's 2019 Global Healthcare Conference

    BOSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today